Title |
(PQD3) Genetic Basis of Breast Cancer Resistance in BRCA1+ Carrier
|
Institution |
UNIVERSITY OF NEBRASKA MEDICAL CENTER, OMAHA, NE
|
Principal Investigator |
WANG, SAN MING
|
NCI Program Director |
Judy Mietz
|
Cancer Activity |
DNA Chromosome Aberrations
|
Division |
DCB
|
Funded Amount |
$174,788
|
Project Dates |
09/01/2013 - 08/31/2015
|
Fiscal Year |
2013
|
Project Type |
Grant
|
Research Topics w/ Percent Relevance |
Cancer Types w/ Percent Relevance |
Cancer (100.0%)
Genetic Testing (100.0%)
|
Breast (100.0%)
|
Research Type |
Cancer Initiation: Alterations in Chromosomes
Cancer Initiation: Oncogenes and Tumor Suppressor Genes
|
Abstract |
DESCRIPTION (provided by applicant): Our proposal addresses the PQD3 in the RFA-CA-12-022: "What underlying causal events - e.g., genetic, epigenetic, biologic, behavioral, or environmental - allow certain individuals to survive beyond the expected limits of otherwise highly lethal cancers?" BRCA1 mutation is one of the best-known genetic causes for breast cancer. In BRCA1+ families, up to 80% of the family members who inherited BRCA1 mutation will develop breast cancer by age of 70, whereas 20% of the family members who also inherited BRCA1 mutation (BRCA1+ carrier) are breast cancer-resistance in that they will never develop breast cancer in their lifetime. In this proposal, we plan to study the genetic basis of breast cancer-resistance. We plan to use exome sequencing method to compare the entire genes between the breast cancer-affected and breast cancer- unaffected pairs from the same BRCA1+ families to identify the genes mutated differently between the two types of family members and to determine their functional relevance to breast cancer. Our proposal directly addresses the PQD3 by identifying the genes that protect the BRCA1+ individuals from breast cancer. |